ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it
ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it shouldtake a charge as a provision for the litigation.
Cafarella filed suit against ISG last month, charging the companywith breach of contract when it dismissed him on Aug. 8 (SCAN8/28/96). Cafarella is claiming damages of $1.5 million (Canadian).
In addition to Cafarella, two other executives associated withthe former Siemens executive have left ISG. They are Denis O'Connor,a Loral veteran who was vice president of sales and marketing,and Gary Hepworth, director of human resources. Both had beenhired by Cafarella, according to ISG's CFO, Gerry McDonald.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.